The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

That’s how much Eli Lilly’s revenue grew in 2024 ... medicines are still tremendous drivers of revenue. The company expects Mounjaro will tally about $3.5 billion in sales for the fourth ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Incretins such as glucagon-like peptide-1, or GLP-1, are used in diabetes and obesity drugs like Eli ... In the company's third-quarter report in October, Lilly reported sales of both Mounjaro ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.jCr9XYTz.js ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.